SonoTran® Particles Patent Granted in the United States and Japan
Oxford, UK – 15th October 2019 – OxSonics therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer announced today that a patent protecting its SonoTran Particles has issued in the US and is proceeding to grant in Japan.
The granted patent claims relate not only to morphological features and methods of production of the SonoTran Particles, but also to their therapeutic and diagnostic use. The patent has today been issued by the US patent office and has also been allowed, and therefore is proceeding to grant, at the Japanese patent office.
Colin Story, CEO commented: “We’re very pleased to see the SonoTran Particle patent applications proceed to grant. In conjunction with the know-how associated with their GMP manufacture, this key proprietary asset is now broadly protected. During the past 2 years patents covering the company’s ‘see as you treat’ technology have also granted across all major territories. The company now has the benefit of combined protection of consumable and hardware components of its ground-breaking platform technology.”
– ENDS –
About OxSonics Therapeutics
OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.
The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.
The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.
OxSonics is based in Oxford in the UK.
For more information please visit: www.oxsonics.com.